Item 1.01. Entry Into a Material Definitive Agreement

As we previously announced, on August 29, 2021, Petra Acquisition, Inc., a Delaware corporation ("Petra"), entered into an agreement and plan of merger (as it may be amended and/or restated from time to time, the "Merger Agreement"), by and among Petra, Petra Acquisition Merger Inc., a Delaware corporation and wholly-owned Subsidiary of Petra ("Merger Sub"), and Revelation Biosciences, Inc., a Delaware corporation ("Revelation"), pursuant to which Merger Sub will merge with and into Revelation with Revelation surviving the merger as a wholly-owned subsidiary of Petra. In addition, in connection with the consummation of the Business Combination, Petra will be renamed "Revelation Biosciences, Inc." ("New Revelation").

The Merger Agreement provides that Petra has agreed to acquire all of the outstanding equity interests of Revelation for an aggregate of 10,500,000 shares of Petra Common Stock, par value $0.001 per share (the "Merger Consideration Shares").

In accordance with the terms and subject to the conditions of the Merger Agreement, at the effective time of the merger (the "Effective Time"), each share of Revelation's common stock, Series A Preferred Stock, and Series A-1 Preferred Stock issued and outstanding immediately prior to the Effective Time shall be cancelled and shall be converted into the right to receive the Per Share Merger Consideration (i.e., the portion of the Merger Consideration Shares with respect to a single share of Revelation's common stock, Series A Preferred Stock or Series A-1 Preferred Stock, as the case may be, equal, in each case, to the quotient obtained by dividing (x) the Merger Consideration Shares by (y) the Fully Diluted Company Shares). As used herein, "Fully Diluted Company Shares" means the sum, without duplication, of (a) all shares of Revelation's common stock that are issued and outstanding immediately prior to the Effective Time; plus (b) all shares of Revelation's Series A Preferred Stock or Series A-1 Preferred Stock (on an as converted to Revelation's common stock basis) that are issued and outstanding immediately prior to the Effective Time; plus (c) the aggregate number of Revelation "Rollover Warrant Shares"; plus (d) the aggregate number of Revelation "Rollover RSU Shares".

In addition, pursuant to the Merger Agreement, at the Effective Time, each Revelation RSU Award (as defined in the Merger Agreement) that is outstanding as of immediately prior to the Effective Time shall be assumed by Petra and shall be converted into that number of whole Parent RSU Awards (as defined in the Merger Agreement) equal to the product (rounded down to the nearest whole number) of: (i) the number of Revelation RSU Awards held by that holder as of immediately prior to the Effective Time; multiplied by (ii) the Common Stock Exchange Ratio (as defined in the Merger Agreement) (a "Parent RSU Award" and collectively, the "Parent RSU Awards"). Further, each Revelation Warrant (as defined in the Merger Agreement) shall be converted into a warrant to purchase, subject to substantially the same terms and conditions as were applicable under such Revelation Warrant, the number of shares of Petra Common Stock (rounded down to the nearest whole share), determined by multiplying the number of shares of Revelation common stock subject to such Revelation Warrant immediately prior to the Effective Time by the Common Stock Exchange Ratio, at an exercise price per share of Petra Common Stock (rounded up to the nearest whole cent) equal to (x) the exercise price per share of Revelation common stock of such Revelation Warrant divided by (y) the Common Stock Exchange Ratio (a "Converted Warrant" and collectively, the "Converted Warrants")).





                                       1




Post-Closing Board of Directors and Executive Officers

Immediately following the closing, Petra's board of directors will consist of five directors, consisting of James Rolke, George F. Tidmarsh, MD, PhD, Jennifer Carver, Jess Roper and Curt LaBelle, MD. At the closing, all of the executive officers of Petra shall resign and the individuals serving as executive officers of Petra immediately after the closing will be the same individuals (in the same offices) as those of Revelation immediately prior to the closing.

Registration Statement and Stockholder Approval

Petra will prepare and file with the Securities and Exchange Commission (the "SEC") a Registration Statement on Form S-4, that will include a preliminary proxy statement/prospectus, and when available, a definitive proxy statement and final prospectus (the "Proxy Statement"), and call a special meeting of the holders of Petra common stock to vote at the meeting (the "Special Meeting"). The holders of the majority of the voting power of Petra's common stock present in person or represented by proxy at the Special Meeting must approve the Merger Agreement, the Business Combination and certain other actions related thereto as provided in the Delaware General Corporation Law, Petra's certificate of incorporation and applicable listing rules of The Nasdaq Stock Market LLC("Nasdaq").

Representations and Warranties; Covenants

Petra, Merger Sub and Revelation have made customary representations, warranties and covenants in the Merger Agreement, including, among other things, covenants with respect to the conduct of Petra and Revelation prior to the closing of the Business Combination. The parties have also agreed to customary "no shop" obligations. The representations and warranties of Petra, Merger Sub and Revelation will not survive the closing of the Business Combination.

Extension of Time to Consummate a Business Combination

Pursuant to Petra's organizational documents, Petra has until October 13, 2021 (the "Consummation Deadline") to consummate its initial business combination. Accordingly, pursuant to the Merger Agreement, Petra has agreed to (a) prepare (with the Revelation's reasonable cooperation) and, not later than September 2, 2021 (or such later date to which the parties mutually agree in writing), file with the SEC a mutually acceptable proxy statement to amend Petra's organizational documents in order to extend the Consummation Deadline to January 13, 2022 (or such earlier date to which the parties mutually agree in writing) (the "Extension Proposal"), (b) solicit proxies from Petra's stockholders to vote in favor of the Extension Proposal, and (c) convene and hold a meeting of the stockholders of Petra to vote upon the Extension Proposal (the "Extension Stockholders' Meeting.")





Closing Conditions


The closing of the Business Combination is subject to certain customary conditions of the respective parties, including, among other things, that: (i) applicable stockholder approval shall have been received; (ii) since the date of the Merger Agreement there shall not have occurred any Effect (as defined in the Merger Agreemeent) in respect of Revelation or Petra, that individually, or together with any other Effect, has had or would reasonably be expected to have a Material Adverse Effect (as defined in the Merger Agreement) in respect of Revelation or Petra, as the case may be; (iii) New Revelation shall have at least $5,000,001 of net tangible assets immediately following the closing (after giving effect to the redemption of public shares by Petra's public stockholders); (iv) Petra's initial listing application in connection with the transactions contemplated by the Merger Agreement shall have been approved by Nasdaq so that immediately following the Business Combination, Petra satisfies any applicable initial and continuing listing requirements of Nasdaq; and (vi) certain Revelation stockholders shall have delivered a lock-up agreement.





                                       2





Termination


The Merger Agreement may be terminated by Petra or Revelation under certain circumstances, including, among others; (i) by mutual written consent of Petra and Revelation and (ii) by either Petra or Revelation if the closing of the Business Combination has not occurred on or before October 13, 2021 (or January 13, 2021, if the Extension Proposal is approved at the Extension Stockholders' Meeting).

The Merger Agreement and the foregoing summary thereof has been included in this Current Report on Form 8-K to provide investors and stockholders with information regarding its terms. It is not intended to provide any other factual information about Petra, Revelation or Merger Sub or any of their respective subsidiaries or affiliates. The representations, warranties and covenants contained in the Merger Agreement were made only for purposes of that agreement and as of specific dates, were solely for the benefit of the parties to the Merger Agreement, may be subject to limitations agreed upon by the contracting parties, including being qualified by disclosures not reflected in the Merger Agreement, were made for the purpose of allocating contractual risk between the parties to the Merger Agreement instead of establishing matters as facts, and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors or stockholders and reports and documents filed with the SEC. Investors and stockholders are not third party beneficiaries under the Merger Agreement and should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of Petra, Revelation or Merger Sub or any of their respective subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in Petra's public disclosures.

The foregoing summary of the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the actual Merger Agreement, which is filed as Exhibit 2.1 hereto, and which is incorporated by reference herein.

Additional Agreements Executed at the Signing of the Merger Agreement





Support Agreements


In connection with the Merger Agreement, certain directors and holders of equity securities of Revelation each entered into a support agreement (the "Company Support Agreement") with Petra and Revelation, pursuant to which each such director and holder of equity securities of Revelation agrees to vote the shares of Revelation capital stock beneficially owned by them in favor of each of the proposals to be included in the applicable written consent of stockholders, to take all actions reasonably necessary to consummate the Business Combination and to vote against any proposal that would prevent the satisfaction of the conditions to the Business Combination set forth in the Merger Agreement.

The foregoing description of the Company Support Agreement is qualified in its entirety by reference to the full text of the form of Company Support Agreement, a copy of which is included as Exhibit A to the Merger Agreement, filed as Exhibit 10.2 to this Current Report on Form 8-K, and incorporated herein by reference.

In connection with the execution of the Merger Agreement, Petra Investment Holdings, LLC, the sponsor of Petra (the "Sponsor"), officers and directors of Petra (the "Insiders") entered into a support agreement (the "Sponsor Support Agreement") with Revelation and Petra, pursuant to which each such Insider agrees to vote all shares of Petra common stock beneficially owned by it in favor of each of the proposals to be presented at the Special Meeting, to take all actions reasonably necessary to consummate the Business Combination and to vote against any proposal that would prevent the satisfaction of the conditions to the Business Combination set forth in the Merger Agreement.





                                       3




The foregoing description of the Sponsor Support Agreement is qualified in its entirety by reference to the full text of the form of Sponsor Support Agreement, a copy of which is included as Exhibit B to the Merger Agreement, filed as Exhibit 10.3 to this Current Report on Form 8-K, and incorporated by reference herein.

Additional Agreement to be Executed at Closing

The Merger Agreement provides that, upon consummation of the Business Combination, New Revelation will enter into the following additional agreement.





Lock-up Agreement


In connection with the closing of the Business Combination, certain stockholders of Revelation will enter into a lock-up agreement (the "Lock-Up Agreement") with Petra, pursuant to which each will agree, subject to certain customary exceptions, not to:

(i) offer, sell, contract to sell, pledge, or otherwise dispose of, directly or indirectly, any shares of Petra common stock or securities convertible into or exercisable or exchangeable for Petra common stock held by it immediately after the Effective Time, or enter into a transaction that would have the same effect;

(ii) enter into any swap, hedge or other arrangement that transfers, in whole or in part, any of the economic consequences of ownership of any of such shares, whether any of these transactions are to be settled by delivery of such shares, in cash or otherwise; or

(iii) publicly announce the intention to make any offer, sale, pledge or disposition, or to enter into any transaction, swap, hedge or other arrangement, or engage in any "Short Sales" (as defined in the Lock-up Agreement) with respect to any security of Petra; until the date that is six months after the consummation of the Business Combination.

The foregoing description of the Lock-Up Agreement is qualified in its entirety by reference to the full text of the form of Lock-up Agreement, a copy of which is included as Exhibit C to the Merger Agreement, filed as Exhibit 10.4 to this Current Report on Form 8-K, and incorporated herein by reference.

Important Information and Where To Find It

In connection with the proposed Business Combination described herein, Petra intends to file relevant materials with the SEC, including a Registration Statement on Form S-4, that includes a preliminary proxy statement/prospectus, and when available, a definitive proxy statement and final prospectus. Promptly after filing its definitive proxy statement with the SEC, Petra will mail the definitive proxy statement and a proxy card to each stockholder entitled to vote at the Special Meeting relating to the transaction. INVESTORS AND STOCKHOLDERS . . .

Item 9.01. Financial Statements and Exhibits





 (d) Exhibits.




Exhibit No.                                Description

2.1*            Agreement and Plan of Merger dated as of August 29, 2021, by and
              among Petra Acquisition Inc., Petra Acquisition Merger Inc. and
              Revelation Biosciences, Inc.
10.2            Form of Company Support Agreement (included as Exhibit A to Exhibit
              2.1)
                Form of Sponsor Support Agreement (included as Exhibit B to Exhibit
              2.1)
10.5            Form of Lock-up Agreement (included as Exhibit C to Exhibit 2.1)
104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document)




*   Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of
    Regulation S-K. The registrant hereby undertakes to furnish copies of any of
    the omitted schedules and exhibits upon request by the U.S. Securities and
    Exchange Commission.




                                       6

© Edgar Online, source Glimpses